

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6777068

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ARIAD PHARMACEUTICALS, INC.		05/03/2021
RECEIVING PARTY DATA		
Name:	TAKEDA PHARMACEUTICAL COMPANY LIMITED	
Street Address:	1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA-SHI	
City:	OSAKA	
State/Country:	JAPAN	
PROPERTY NUMBERS Total: 27		
Property Type	Number	
Patent Number:	6706699	
Patent Number:	7009054	
Patent Number:	6713462	
Patent Number:	7019139	
Patent Number:	8071609	
Patent Number:	8586566	
Patent Number:	7432277	
Patent Number:	8912330	
Patent Number:	9024028	
Patent Number:	9573934	
Patent Number:	9834518	
Patent Number:	9834571	
Application Number:	17193502	
Patent Number:	6878697	
Patent Number:	9611283	
Application Number:	17124407	
Patent Number:	10934317	
Patent Number:	10385078	
Patent Number:	9273077	
Application Number:	16672205	
Patent Number:	9012462	

PATENT

Property Type	Number
Patent Number:	8846664
Patent Number:	9796712
Application Number:	16853954
Patent Number:	10227342
Application Number:	16982378
Application Number:	62645089

CORRESPONDENCE DATA

Fax Number: (202)416-7212

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2028356212

Email: nhia.lee@bakermckenzie.com

Correspondent Name: BAKER & MCKENZIE LLP

Address Line 1: 815 CONNECTICUT AVENUE, NW

Address Line 2: ATTN: NHIA LEE

Address Line 4: WASHINGTON, D.C. 20006

ATTORNEY DOCKET NUMBER: 50582642-0000

NAME OF SUBMITTER: NHIA LEE

SIGNATURE: /Nhia Lee/

DATE SIGNED: 06/23/2021

Total Attachments: 4

source=USA - EXECUTED - M4_ARIAD_Confirmatory_Assignment#page1.tif

source=USA - EXECUTED - M4_ARIAD_Confirmatory_Assignment#page2.tif

source=USA - EXECUTED - M4_ARIAD_Confirmatory_Assignment#page3.tif

source=USA - EXECUTED - M4_ARIAD_Confirmatory_Assignment#page4.tif

CONFIRMATORY PATENT ASSIGNMENT

WHEREAS, on the 3rd day of May 2021, ARIAD Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA, and having a place of business at 40 Landsdowne Street, Cambridge, MA 02139 (the "Assignor"), was the owner of the patent(s) and application(s) identified in attached Schedule A ("the Patent(s)"); and

WHEREAS, on the 3rd day of May 2021, Takeda Pharmaceutical Company Limited, a public stock corporation organized under the laws of Japan and having a place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, Japan (the "Assignee"), was desirous of acquiring the Patent(s), and related invention(s) thereof;


NOW, THEREFORE Assignor confirms that effective on the 3rd day of May 2021, for good and valuable consideration, the receipt of which was acknowledged therein and is hereby confirmed, Assignor sold, assigned and transferred unto said Assignee, and Assignee's successors and assigns, all right, title and interest in and to the Patent(s), and the invention(s) disclosed and claimed therein, and any Letters Patent which may thereafter be granted on the same in the United States and all countries throughout the world including any reissues, divisions, renewals, continuations in whole or in part, substitutions, conversions, reexaminations, prolongations, provisionals or extensions thereof, as well as rights to any and all existing causes of action and the right to past damages associated therewith, and all rights under the Paris Convention for the Protection of Industrial Property, the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patent(s) may be granted as fully and entirely as the same would have been held and enjoyed by Assignor had the sale and assignment not been made.

Assignor hereby further confirms that Assignee was granted the right to update the bibliographic information found in the attached Schedule A from time to time, including but not limited to adding the patent application numbers and patent numbers for those filings that fall under the scope of the above grant, such that this Agreement can be recorded with the respective global patent offices and ministries.

Assignee hereby grants a limited power of attorney for the purpose of recording this assignment in the United States and all other countries throughout the world to the practitioners listed on the power of attorney attached herewith and further grant the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office or any other patent office worldwide for recordation of this document.

IN WITNESS WHEREOF, Assignor, by its duly authorized officer, has executed this Confirmatory Assignment in Lexington, Massachusetts, USA as of this 3rd day of May 2021.

ON BEHALF OF ARIAD Pharmaceuticals, Inc.

By: 

Printed Name: Constance Yeung
Title: Authorized Signatory, IP Region Head


STATE OF MASSACHUSETTS


§
§
§

COUNTY OF MIDDLESEX


On this 3rd day of May 2021, before me, NOREEN BUCKLEY, Notary Public, personally appeared Constance Yeung, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.






Noreen Buckley
NOTARY PUBLIC
My Commission Expires: 28 September 2023



IN WITNESS WHEREOF, Assignee, by its duly authorized officer, has executed this Confirmatory Assignment in Sudbury,
Massachusetts, USA as of this 3rd day of May 2021.

ON BEHALF OF Takeda Pharmaceutical Company Limited

By: 

Printed Name: Patrick Eagleman
Title: Authorized Signatory, VP Intellectual Property


STATE OF MASSACHUSETTS


§
§
§

COUNTY OF MIDDLESEX

On this 3rd day of May 2021, before me, NOREEN BUCKLEY, Notary Public, personally appeared Patrick Eagleman, personally known to me or identified by me to be the person whose name is subscribed to the within instrument and evidenced to me that they executed the same in their authorized capacity, and that by their signature on the instrument the person, or the entity upon behalf of which the person acted, executed the instrument.

WITNESS my hand and official seal.





Noreen Buckley
NOTARY PUBLIC
My Commission Expires: 28 September 2023

Schedule A

Patent No.	Family	Status	Country	App. No.	Filing Date	Pub. No.	Assignor
403A US	403A	Granted	USA	10/177990	2002-06-21	6706699	ARIAD Pharmaceuticals, Inc.
403A USC1	403A	Granted	USA	10/716239	2003-11-17	7009054	ARIAD Pharmaceuticals, Inc.
406A US	406A	Granted	USA	10/177500	2002-06-21	6713462	ARIAD Pharmaceuticals, Inc.
406A USC1	406A	Granted	USA	10/715794	2003-11-17	7019139	ARIAD Pharmaceuticals, Inc.
424A PCT/US	424A	Granted	USA	11/990299	2006-11-08	8071609	ARIAD Pharmaceuticals, Inc.
424A PCT/USC1	424A	Granted	USA	13/311106	2011-05-12	8586566	ARIAD Pharmaceuticals, Inc.
431 US	431	Granted	USA	11/429582	2006-05-05	7432277	ARIAD Pharmaceuticals, Inc.
451 PCT/US	451	Granted	USA	12/998873	2009-11-12	8912330	ARIAD Pharmaceuticals, Inc.
460A PCT/US	460A	Granted	USA	13/981051	2012-01-26	9024028	ARIAD Pharmaceuticals, Inc.
460A PCT/USC1	460A	Granted	USA	14/607831	2015-01-28	9573934	ARIAD Pharmaceuticals, Inc.
462A US	462A	Granted	USA	13/464921	2012-04-05	9834518	ARIAD Pharmaceuticals, Inc.
465C PCT/USC1	465C	Granted	USA	15/044382	2016-02-16	9834571	ARIAD Pharmaceuticals, Inc.
PAT12898CONUS05	12898	Pending	USA	17/193502	2021-03-05		ARIAD Pharmaceuticals, Inc.
PAT15022US02	15022	Granted	USA	10/177469	2002-06-21	6878697	ARIAD Pharmaceuticals, Inc.
PAT17424US02	17424	Granted	USA	14/249483	2014-04-10	9611283	ARIAD Pharmaceuticals, Inc.
PAT17425CONUS04	17425	Pending	USA	17/124407	2020-12-16		ARIAD Pharmaceuticals, Inc.
PAT17425DIVUS03	17425	Granted	USA	16/429988	2019-06-03	10934317	ARIAD Pharmaceuticals, Inc.
PAT17425PCTUS02	17425	Granted	USA	15/520694	2015-10-21	10385078	ARIAD Pharmaceuticals, Inc.
PAT18392CIPUS03	8392	Granted	USA	13/842951	2013-03-15	9273077	ARIAD Pharmaceuticals, Inc.
PAT18392DIVUS10	8392	Pending	USA	16/672205	2019-11-01		ARIAD Pharmaceuticals, Inc.
PAT18392PCTUS02	8392	Granted	USA	12/736910	2009-05-21	9012462	ARIAD Pharmaceuticals, Inc.
PAT18922PCTUS02	8922	Granted	USA	12/998634	2009-11-12	8846664	ARIAD Pharmaceuticals, Inc.
PAT18923CONUS03	8923	Granted	USA	15/600023	2017-05-19	9796712	ARIAD Pharmaceuticals, Inc.
PAT18923CONUS06	8923	Pending	USA	16/853954	2020-04-21		ARIAD Pharmaceuticals, Inc.
PAT18923PCTUS02	8923	Granted	USA	15/319637	2015-05-13	10227342	ARIAD Pharmaceuticals, Inc.
PAT19627PCTUS02	489	Pending	USA	16/982378	2019-03-18		ARIAD Pharmaceuticals, Inc.
PAT19627PRIUS01PRO	489	Inactive	USA	62/645089	2018-03-19		ARIAD Pharmaceuticals, Inc.

PATENT

REEL: 056637 FRAME: 0884